Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Timing of rhPSMA-7.3 (18F) in Recurrent Prostate Cancer
NCT05678322Phase 3Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by NYU Langone Health. Primary endpoints: Positive Prostate Cancer Screens at Baseline and Positive Prostate Cancer Screens at Second Scan Visit. Started Jan 2023; status: active, not recruiting.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05678322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678322.